“…Sulfur incorporation can significantly expand the structural diversity and bioactivities of many naturally occurring molecules ( Hai et al, 2021 ), many sulfur-containing natural products, such as penicillin and ixabepilone, have been approved for clinic therapy. However, bacterial sulfur-containing aromatic polyketides are relatively rare, with only a few examples reported over the past decades ( Etoh et al, 1987 ; Ohta et al, 1987 ; Rohr and Zeeck, 1987 ; Miyata et al, 1992 ; Aoyama et al, 1993 ; Carney et al, 1997 ; Kulanthaivel et al, 1999 ; Sasaki et al, 2010 ; Taguchi et al, 2013 ; Wang et al, 2013 ; Woo et al, 2013 ; Taguchi et al, 2015 ; Bilyk et al, 2016 ; Che et al, 2016 ; Xie et al, 2016 ; Nakashima et al, 2017 ; Matsuo et al, 2019a ; Bae et al, 2019 ; Matsuo et al, 2019b ; He et al, 2019 ; Fang et al, 2020 ; Cao et al, 2021 ). Amongst these reports, naquihexcin A could inhibit the proliferation of the adriamycin resistant human breast cancer ( Che et al, 2016 ); nanaomycin K showed an inhibitory effect on the epithelial-mesenchymal transition ( Matsuo et al, 2019a ); and naquihexcin E exhibited a notable anti-HIV activity ( He et al, 2019 ).…”